Celadon Pharmaceuticals PLC
LSE:CEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Celadon Pharmaceuticals PLC
Accounts Receivables
Celadon Pharmaceuticals PLC
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Celadon Pharmaceuticals PLC
LSE:CEL
|
Accounts Receivables
£25m
|
CAGR 3-Years
647%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Croda International PLC
LSE:CRDA
|
Accounts Receivables
£363.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Science in Sport PLC
LSE:SIS
|
Accounts Receivables
£11.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Venture Life Group PLC
LSE:VLG
|
Accounts Receivables
£9.5m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
11%
|
|
|
Provexis PLC
LSE:PXS
|
Accounts Receivables
£255.1k
|
CAGR 3-Years
22%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
|
A
|
Akanda Corp
NASDAQ:AKAN
|
Accounts Receivables
$356.1k
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Celadon Pharmaceuticals PLC
Glance View
Summerway Capital Plc engages in acquiring companies or businesses that has the potential for strategic, operational, and performance improvement. The firm is engaged in research, cultivation, manufacturing and supply of cannabinoid-based medicines. The firm is focused on growing indoor hydroponic cannabis initially for the chronic pain market. The company is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions such as autism. The firm's facility comprises an indoor, closed-loop hydroponic system to ensure cannabis plants are cultivated under a highly specific climate, light and with irrigation control. The firm's subsidiary, LVL Health is a medical cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal products to treat chronic pain in the United Kingdom.
See Also
What is Celadon Pharmaceuticals PLC's Accounts Receivables?
Accounts Receivables
25m
GBP
Based on the financial report for Dec 31, 2024, Celadon Pharmaceuticals PLC's Accounts Receivables amounts to 25m GBP.
What is Celadon Pharmaceuticals PLC's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
647%
Over the last year, the Accounts Receivables growth was -88%. The average annual Accounts Receivables growth rates for Celadon Pharmaceuticals PLC have been 647% over the past three years .
